Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II randomized double-blind placebo-controlled study of SCTT11 in healthy volunteers and patients with moderate-to-severe thyroid eye disease
CTR20251087Phase 2Active
- Sponsor
- Sinocelltech Group Limited
- Start
- Mar 2025
- Countries
- 1
01
Overview
A Phase 2 trial of SCTT11 in Graves Orbitopathy (GO), sponsored by Sinocelltech Group Limited. Started Mar 2025; status: active.
02
Drugs
SCTT11
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20251087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251087.